Braxia Scientific
eröffnet am 18.05.21 10:24:40 von
neuester Beitrag 07.04.24 04:14:20 von
neuester Beitrag 07.04.24 04:14:20 von
Beiträge: 225
ID: 1.347.745
ID: 1.347.745
Aufrufe heute: 0
Gesamt: 36.210
Gesamt: 36.210
Aktive User: 0
ISIN: CA1057361026 · WKN: A3CPBM
0,0088
EUR
+25,00 %
+0,0018 EUR
Letzter Kurs 15:20:38 Lang & Schwarz
Neuigkeiten
Werte aus der Branche Getränke/Tabak
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5.300,00 | +99.999,00 | |
| 1,4600 | +21,67 | |
| 36,97 | +11,46 | |
| 2.040,45 | +9,72 | |
| 1,8450 | +9,17 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4700 | -7,84 | |
| 0,9630 | -8,29 | |
| 1.100,00 | -8,33 | |
| 5,7675 | -9,74 | |
| 0,7700 | -45,00 |
Beitrag zu dieser Diskussion schreiben
Feedback
Q3 2024 Financial Summary and Recent Highlights
https://www.marketscreener.com/quote/stock/BRAXIA-SCIENTIFIC…
Revenue increased 0.7% to $0.492 million year-over-year for the three months ended December 31, 2023.
Revenue increased 23.9% to $1.69 million year-over-year for the nine months ended December 31, 2023.
Net loss was $0.904 million for the three months ended December 31, 2023, compared to a net loss of $2.17 million for the three months ended December 31, 2022.
Net loss was $2.17 million for the nine months ended September 30, 2023, compared to a net loss of $5.48 million for the nine months ended December 31, 2022.
As at December 31, 2023, the Company's cash and cash equivalents were $0.128 million with a working capital deficit of $1.81 million.
https://www.marketscreener.com/quote/stock/BRAXIA-SCIENTIFIC…
Revenue increased 0.7% to $0.492 million year-over-year for the three months ended December 31, 2023.
Revenue increased 23.9% to $1.69 million year-over-year for the nine months ended December 31, 2023.
Net loss was $0.904 million for the three months ended December 31, 2023, compared to a net loss of $2.17 million for the three months ended December 31, 2022.
Net loss was $2.17 million for the nine months ended September 30, 2023, compared to a net loss of $5.48 million for the nine months ended December 31, 2022.
As at December 31, 2023, the Company's cash and cash equivalents were $0.128 million with a working capital deficit of $1.81 million.
Braxia Scientific Reports Mandatory Conversion of Debentures
Newsfile - Newsfile - Mon Jan 15, 4:44PM CST
Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share.
https://www.newsfilecorp.com/release/194298
Newsfile - Newsfile - Mon Jan 15, 4:44PM CST
Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share.
https://www.newsfilecorp.com/release/194298
Braxia Scientific Corp.: Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR+), the electronic filing system for the disclosure documents of issuers across Canada, at www.sedarplus.ca.
Dr. Roger McIntyre, CEO, Braxia Scientific commented, "Our clinics experienced higher treatment volumes in the first half of fiscal 2024 resulting in strong revenue growth. This demonstrates the demand for critical mental health treatments and therapies that our team of specialized psychiatrists, doctors and nurses provide across our clinical footprint. Our team has continued to focus on reducing expenses and improving efficiencies while also looking to add novel therapies and other support services to our clinical platform to further improve revenues."
"Looking ahead, the Board has formally initiated a process to explore strategic alternatives and alternative sources of capital or partnerships that may be available to the Company following continued challenges in the economic environment and in accessing capital through public markets. While I remain confident in the continued growth of our clinics, if we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring and the potential scaling back of clinic locations."
Q2 2024 Financial Summary and Recent Highlights
Revenue increased 30.5% to $0.594 million year-over-year for the three months ended September 30, 2023.
Revenue increased 36.8% to $1.19 million year-over-year for the six months ended September 30, 2023.
Net loss was $0.275 million for the three months ended September 30, 2023, compared to a net loss of $2.16 million for the three months ended September 30, 2022.
Net loss was $1.08 million for the six months ended September 30, 2023, compared to a net loss of $3.13 million for the six months ended September 30, 2022.
As at September 30, 2023, the Company's cash and cash equivalents were $0.701 million with a working capital deficit of $0.961 million.
Corporate Update
The Company continued to make progress on its revenue generation and expense reduction initiatives as well as streamlining its operations to prioritize preservation of capital. After further review and in consultation with its legal advisors, the Board of Directors has decided to formally initiate a process to explore strategic alternatives that may be available to the Company to unlock shareholder value. The comprehensive process will begin immediately and will evaluate a broad range of options, including a potential sale of the Company, a merger or other business combination, a sale of all or a portion of the Company's assets, strategic investment or other significant transaction. Braxia has received strategic inquiries from multiple parties over the past few months.
The Company has not set a timetable for completion of the process and does not intend to provide any updates on developments unless and until the Company executes a definitive agreement with respect thereto, or the Board otherwise determines that an update is appropriate or required.
While the Company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.
The Company also announced the resignation of Olga Cwiek from Braxia Scientific's Board of Directors effective November 28, 2023. Peter Rizakos, Chief Legal Officer, has been appointed to the Board of Directors. Additionally, the Company announced the departure of Stephen Brooks, Chief Financial Officer, to pursue an opportunity in the private sector. Peter Rizakos, Chief Legal Officer, has been named Chief Financial Officer.
"We thank both Olga and Stephen for their service to Braxia Scientific and wish them success in their future endeavors," said Dr. McIntyre.
https://www.finanznachrichten.de/nachrichten-2023-11/6080466…
Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR+), the electronic filing system for the disclosure documents of issuers across Canada, at www.sedarplus.ca.
Dr. Roger McIntyre, CEO, Braxia Scientific commented, "Our clinics experienced higher treatment volumes in the first half of fiscal 2024 resulting in strong revenue growth. This demonstrates the demand for critical mental health treatments and therapies that our team of specialized psychiatrists, doctors and nurses provide across our clinical footprint. Our team has continued to focus on reducing expenses and improving efficiencies while also looking to add novel therapies and other support services to our clinical platform to further improve revenues."
"Looking ahead, the Board has formally initiated a process to explore strategic alternatives and alternative sources of capital or partnerships that may be available to the Company following continued challenges in the economic environment and in accessing capital through public markets. While I remain confident in the continued growth of our clinics, if we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring and the potential scaling back of clinic locations."
Q2 2024 Financial Summary and Recent Highlights
Revenue increased 30.5% to $0.594 million year-over-year for the three months ended September 30, 2023.
Revenue increased 36.8% to $1.19 million year-over-year for the six months ended September 30, 2023.
Net loss was $0.275 million for the three months ended September 30, 2023, compared to a net loss of $2.16 million for the three months ended September 30, 2022.
Net loss was $1.08 million for the six months ended September 30, 2023, compared to a net loss of $3.13 million for the six months ended September 30, 2022.
As at September 30, 2023, the Company's cash and cash equivalents were $0.701 million with a working capital deficit of $0.961 million.
Corporate Update
The Company continued to make progress on its revenue generation and expense reduction initiatives as well as streamlining its operations to prioritize preservation of capital. After further review and in consultation with its legal advisors, the Board of Directors has decided to formally initiate a process to explore strategic alternatives that may be available to the Company to unlock shareholder value. The comprehensive process will begin immediately and will evaluate a broad range of options, including a potential sale of the Company, a merger or other business combination, a sale of all or a portion of the Company's assets, strategic investment or other significant transaction. Braxia has received strategic inquiries from multiple parties over the past few months.
The Company has not set a timetable for completion of the process and does not intend to provide any updates on developments unless and until the Company executes a definitive agreement with respect thereto, or the Board otherwise determines that an update is appropriate or required.
While the Company intends to evaluate all options fairly to maximize shareholder value, there can be no assurance that the strategic review process will result in any transaction, or if a transaction is undertaken, as to its terms or timing.
The Company also announced the resignation of Olga Cwiek from Braxia Scientific's Board of Directors effective November 28, 2023. Peter Rizakos, Chief Legal Officer, has been appointed to the Board of Directors. Additionally, the Company announced the departure of Stephen Brooks, Chief Financial Officer, to pursue an opportunity in the private sector. Peter Rizakos, Chief Legal Officer, has been named Chief Financial Officer.
"We thank both Olga and Stephen for their service to Braxia Scientific and wish them success in their future endeavors," said Dr. McIntyre.
https://www.finanznachrichten.de/nachrichten-2023-11/6080466…
Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
C.BRAX | June 9, 2023
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure
Toronto, Ontario--(Newsfile Corp. - June 9, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company with mental health clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from 2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experience increased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased 87.2% to 571 from 305 treatments on a year-over-year basis following the completion of construction and opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterloo clinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214 treatments in its first 8 months of operation.
"Over the last few years, Braxia has built a tremendous patient base and reputation for providing innovative, life-saving treatments for people suffering from major depressive disorder, among other mental health conditions. We have seen record levels of referrals which we expect to continue and convert to treatments as we realign and refocus resources to our clinics," said Dr. Roger McIntyre, CEO, Braxia Scientific.
The Company also reported its current clinic volumes continued to trend up over the last four months through May 2023, with total average monthly treatments up to 307 treatments per month compared with 293 for fiscal 2023. Clinic treatment volumes continue to trend upwards despite executing very little marketing. In the near term, the Company expects to continue to increase its volumes by ramping up direct marketing efforts and improving efficiency with additional capacity planned to come online in September 2023.
Dr. McIntyre added, "To date, patient acquisition growth has largely been driven by our medical team's reputation, relationships and educational programs with primary care physicians and other healthcare providers within the communities we serve versus direct marketing efforts. Looking ahead, we are extremely well positioned to rapidly grow volumes and revenues by expanding our flagship clinic in the Greater Toronto Area, which remains a highly underserved market, and expanding in other major urban centres."
Cost Improvements
Additionally, the Company announced it is taking strategic actions as part of a restructuring plan that prioritizes the growth of its brick-and-mortar clinics while also reducing and rightsizing its cost structure including the slowdown of its US based telemedicine business, KetaMD, Inc. (KetaMD).
The restructuring plan includes a reorganization of its clinic operations, a reduction in certain management positions, and voluntary salary reductions to preserve cash as it works through challenging market conditions and recent potential regulatory changes with respect to virtual at home treatments. As part of the restructuring plan, the Braxia senior management team, including Dr. McIntyre, has voluntarily agreed to reduce cash compensation by an aggregate of $113,000 per month.
"We embarked on an ambitious plan to quickly expand and bring our expertise across North America to reach millions more in need. However, in the last few months we've seen our environment significantly change and as a result we must focus on refining our strategy and potential other structural changes to take us through to the next phase of accelerated growth of our clinics and better execute our strategy."
https://stockhouse.com/news/press-releases/2023/06/09/braxia…
C.BRAX | June 9, 2023
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure
Toronto, Ontario--(Newsfile Corp. - June 9, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company with mental health clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from 2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experience increased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased 87.2% to 571 from 305 treatments on a year-over-year basis following the completion of construction and opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterloo clinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214 treatments in its first 8 months of operation.
"Over the last few years, Braxia has built a tremendous patient base and reputation for providing innovative, life-saving treatments for people suffering from major depressive disorder, among other mental health conditions. We have seen record levels of referrals which we expect to continue and convert to treatments as we realign and refocus resources to our clinics," said Dr. Roger McIntyre, CEO, Braxia Scientific.
The Company also reported its current clinic volumes continued to trend up over the last four months through May 2023, with total average monthly treatments up to 307 treatments per month compared with 293 for fiscal 2023. Clinic treatment volumes continue to trend upwards despite executing very little marketing. In the near term, the Company expects to continue to increase its volumes by ramping up direct marketing efforts and improving efficiency with additional capacity planned to come online in September 2023.
Dr. McIntyre added, "To date, patient acquisition growth has largely been driven by our medical team's reputation, relationships and educational programs with primary care physicians and other healthcare providers within the communities we serve versus direct marketing efforts. Looking ahead, we are extremely well positioned to rapidly grow volumes and revenues by expanding our flagship clinic in the Greater Toronto Area, which remains a highly underserved market, and expanding in other major urban centres."
Cost Improvements
Additionally, the Company announced it is taking strategic actions as part of a restructuring plan that prioritizes the growth of its brick-and-mortar clinics while also reducing and rightsizing its cost structure including the slowdown of its US based telemedicine business, KetaMD, Inc. (KetaMD).
The restructuring plan includes a reorganization of its clinic operations, a reduction in certain management positions, and voluntary salary reductions to preserve cash as it works through challenging market conditions and recent potential regulatory changes with respect to virtual at home treatments. As part of the restructuring plan, the Braxia senior management team, including Dr. McIntyre, has voluntarily agreed to reduce cash compensation by an aggregate of $113,000 per month.
"We embarked on an ambitious plan to quickly expand and bring our expertise across North America to reach millions more in need. However, in the last few months we've seen our environment significantly change and as a result we must focus on refining our strategy and potential other structural changes to take us through to the next phase of accelerated growth of our clinics and better execute our strategy."
https://stockhouse.com/news/press-releases/2023/06/09/braxia…
Ist schon itneressant das Irwin die besten Wuensche dem Braxia Management gibt.
Nachdem das Braxia Management ja das LIFE Offering and Concurrent Private Placement losgetreten hat.
Man wird sehen ob das eine gute Sache war.
Nachdem das Braxia Management ja das LIFE Offering and Concurrent Private Placement losgetreten hat.
Man wird sehen ob das eine gute Sache war.
Trading Spotlight
No deal with Irwin
Irwin Naturals Inc.: Update on LOI for Business Combination with Braxia Scientific Corp.
03/21/2023 | 08:08am EDT
LOS ANGELES - Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ('Irwin' or the 'Company'), announced today that it has terminated the non-binding amended and restated letter of intent ('LOI') for a business combination with Braxia Scientific Corp. ('Braxia'), (the 'Proposed Transaction'). The Company's news release dated January 27, 2023, contained full details of the Proposed Transaction.
CEO of Irwin Naturals, Klee Irwin, expressed disappointment on the announcement but recognized the decision was based on a lack of a clear business rationale for the Company to move forward with the transaction. Despite this, he expressed his admiration for the Braxia management team and wished them well in their future endeavors.
https://www.marketscreener.com/quote/stock/BRAXIA-SCIENTIFIC…
Irwin Naturals Inc.: Update on LOI for Business Combination with Braxia Scientific Corp.
03/21/2023 | 08:08am EDT
LOS ANGELES - Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ('Irwin' or the 'Company'), announced today that it has terminated the non-binding amended and restated letter of intent ('LOI') for a business combination with Braxia Scientific Corp. ('Braxia'), (the 'Proposed Transaction'). The Company's news release dated January 27, 2023, contained full details of the Proposed Transaction.
CEO of Irwin Naturals, Klee Irwin, expressed disappointment on the announcement but recognized the decision was based on a lack of a clear business rationale for the Company to move forward with the transaction. Despite this, he expressed his admiration for the Braxia management team and wished them well in their future endeavors.
https://www.marketscreener.com/quote/stock/BRAXIA-SCIENTIFIC…
Ach hier noch der link https://braxiascientific.com/news/
Ich glaube die Lichter gehen nicht aus, sonst waeren die Aktien fuer 0.055$ und die Warrents fuer 0.07$ nicht verkauft worden, oder?
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
TORONTO, ONTARIO February 27, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the “LIFE Offering”), resulting in the issuance of 13,658,524 units of the Company (each a “Unit”) at a price of $0.055 per Unit for aggregate proceeds of $751,218.83 (the “LIFE First Tranche”). Each Unit consists of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant entitles its holder to purchase one additional Common Share at an exercise price of $0.07 for a period of 36 months from the date of issue....
Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement
TORONTO, ONTARIO February 27, 2023 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the “LIFE Offering”), resulting in the issuance of 13,658,524 units of the Company (each a “Unit”) at a price of $0.055 per Unit for aggregate proceeds of $751,218.83 (the “LIFE First Tranche”). Each Unit consists of one common share of the Company (each a “Common Share”) and one Common Share purchase warrant (each a “Warrant”). Each Warrant entitles its holder to purchase one additional Common Share at an exercise price of $0.07 for a period of 36 months from the date of issue....
Schade, gehen jetzt die Lichter aus??
Toronto, Ontario--(Newsfile Corp. - 16. März 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia" oder das "Unternehmen"), ein Unternehmen für medizinische Forschung und Telemedizin mit Kliniken, die innovative Ketamin- und Psilocybin-Behandlungen für Depressionen und verwandte Störungen anbieten, gibt bekannt, dass Irwin Naturals Inc. ("Irwin") die unverbindliche geänderte und neu gefasste Absichtserklärung ("LOI") für einen Unternehmenszusammenschluss zwischen Irwin und Braxia (die "geplante Transaktion") gekündigt hat. Alle Einzelheiten der vorgeschlagenen Transaktion waren in der Pressemitteilung des Unternehmens vom 27. Januar 2023 enthalten.
Quelle: CEO.CA
Quelle: CEO.CA
Durchsuchen
